Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03998176 · ClinicalTrials.gov registry record · Phase 4
Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE
A Phase 4 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT03998176 is a Phase 4 study that has completed, run by University of Nebraska. The registered enrollment target is 43 participants.
The verdict
NCT03998176, a Phase 4 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected patients who actively use illicit substances. The study will also evaluate retention in care and adherence to B/F/TAF by self-report and pharmacokinetic analysis.
Interventions
- DRUG Bictegravir/emtricitabine/tenofovir alafenamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-10-09 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03998176
The ClinicalTrials.gov registry entry for NCT03998176 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bictegravir/emtricitabine/tenofovir alafenamide is the first listed.
NCT03998176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03998176 about?
NCT03998176 is a clinical study titled "Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE". This study will evaluate the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected patients who actively use illicit substances. The study will also evaluate retention in care and adherence to B/F/TAF by self-report and pharmacokinetic analysis.
What is the current status of trial NCT03998176?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2019-10-09. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT03998176?
The interventions under investigation include: Bictegravir/emtricitabine/tenofovir alafenamide (DRUG).
Who is sponsoring clinical trial NCT03998176?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.